Nevanac (Nepafenac) Patent Expiration, LOE Window & CMS Spending

Nevanac (Nepafenac) by Harrow Eye: FDA Orange Book LOE 2027-01-31, 0 AB generics, $1.9M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHarrow Eye
FDA Application & PathwayN021862 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2027-01-31
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.9M
2024 Medicare Part D Spend$1.7M
2024 Medicaid Spend$153K
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 21.2% 2-yr change)